Travere Therapeutics, Inc.
NASDAQ:TVTX · NASDAQ Global Market
+$0.65 today
Vol 6.59M · Avg 2.31M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+280.61%
Period High
$55.15
Period Low
$14.49
Latest
$55.15
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.47B
Legend Biotech Corporation
NASDAQ:LEGN
$5.44B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.21B
Celcuity Inc.
NASDAQ:CELC
$4.16B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.73B
Disc Medicine, Inc.
NASDAQ:IRON
$2.72B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.70B
Ascentage Pharma Group International
NASDAQ:AAPG
$398.35M
What is the latest TVTX filing?
The latest filing shown is S-8 dated Jun 17, 2026.
How many recent filings does TVTX have?
Intrinsic Alpha currently shows 20 recent filings for TVTX.
Explore More
Continue the stock analysis
Jump to another research area for this company.